In May of this year, Senseonics signed an exclusive distribution with Roche for the commercialization of Senseonics’ Eversense® Continuous Glucose Monitoring System in Germany, Italy and the Netherlands.

Under the terms of the expanded agreement, Senseonics has granted Roche exclusive rights to promote, market, and sell the Eversense product line to diabetes clinics and patients in the covered territories.

“The partnership we formed with Roche earlier this year is off to a promising start. The early success and experience that each of our teams are gaining drove the mutual decision to expand our relationship.

“We are excited to add these additional countries and look forward to growing the presence of Eversense through this partnership,” said Tim Goodnow, CEO and President of Senseonics.

Senseonics will retain responsibility for product development, regulatory approval, quality management, and manufacturing, while Roche will be responsible for sales, marketing, customer support and distribution activities in the covered territories.

Senseonics Holdings, Inc. is a medical technology company focused on the design, development and commercialization of glucose monitoring products designed to help people with diabetes confidently live their lives with ease. Senseonics’ first generation CGM system, Eversense®, includes a small sensor, smart transmitter and mobile application.

Based on fluorescence sensing technology, the sensor is designed to be inserted subcutaneously and communicate with the smart transmitter to wirelessly transmit glucose levels to a mobile device.